Shiva Bhowmik | Chief Scientific Officer
Trio Pharmaceutials, Inc.

Dr. Shiva Bhowmik is the Founder + Chief Scientific Officer at TRIO Pharmaceuticals, Inc.. He is a pioneer in targeted protein and antibody therapeutics, including the development of TRIO’s platform. He is also a recognized expert in the fields of immuno-oncology, antibody, and protein engineering. Prior to TRIO, Dr. Bhowmik was the Program Leader at Ambrx Inc. and ImmunoBrain Checkpoint Inc., where he led the development of the first targeted antibody therapeutic against prostate cancer and Alzheimer’s, which are currently in clinical trials. At ImmunoBrain Checkpoint Inc., he setup a simultaneous pre-clinical and clinical development that led to a shortened path to the clinic. Dr. Bhowmik has led cross-functional and multi-country teams involving R&D, clinical, business, legal, and regulatory providing strategic oversight that led to shortened pre-clinical development. Dr. Bhowmik is the lead inventor on patents for targeted antibody therapeutics. He received a Ph.D. in Biophysics from Purdue University.